Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
12. August 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company focused on gaining regulatory clarity for late-stage lenabasum program and advancing programs targeting the endocannabinoid system and integrins into the clinicAugmenting the pipeline through...
Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases
01. Juni 2021 07:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Corbus diversifies pipeline with two new mAbs that target integrins that inhibit activation of TGFβ High potency anti-αvβ8 mAb licensed from University of California San Francisco and...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress
25. Mai 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 25, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
19. Mai 2021 09:20 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates
13. Mai 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021 Company focused on advancing cannabinoid programs in metabolic diseases and cancer into the clinic in 2022Corbus...
Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences
11. Mai 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
30. März 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU,...
Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases
20. Januar 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist...
Corbus Pharmaceuticals to Report Third Quarter Results on November 10, 2020
03. November 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Company to host conference call and webcast on Tuesday, November 10 at 8:30 a.m. ET Norwood, MA, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Announces Presentation of Data from its Phase 2b Study in Cystic Fibrosis at NACFC 2020
23. Oktober 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...